Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations

被引:25
作者
Maes, Helena [1 ]
Delforge, Michel [1 ]
机构
[1] Univ Leuven, Dept Hematol, Herestr 49, B-3000 Louvain, Belgium
关键词
elderly; geriatric assessment; multiple myeloma; quality of life; tailored therapy; TRANSPLANT-INELIGIBLE PATIENTS; HIGH-DOSE DEXAMETHASONE; ELDERLY-PATIENTS; GERIATRIC ASSESSMENT; ADVERSE EVENTS; OLDER PATIENTS; PHASE-III; BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;
D O I
10.1586/17474086.2015.1021772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is a plasma cell neoplasm with a chronic disease course that primarily affects elderly individuals. The introduction of novel agents such as thalidomide, lenalidomide and bortezomib has significantly improved the outcome for MM patients, including the elderly. Quality of life in MM is influenced by disease-related symptoms, treatment-related toxicity and treatment response. In addition to conventional endpoints as response, quality of life should be carefully evaluated during each therapeutic phase. Caring for older adults with MM is particularly challenging because of the heterogeneity of aging and the presence of comorbidities and frailty, with a potential risk of over- or under-treatment. Moreover, elderly patients may sometimes prioritize maintaining quality of life above prolonging survival. A careful evaluation of comorbidities and a geriatric assessment can facilitate risk-stratification of elderly patients to identify the older population fit enough to tolerate standard drug dosing, and to detect the frail patients who need age-adapted treatment.
引用
收藏
页码:355 / 366
页数:12
相关论文
共 59 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience [J].
Alegre, Adrian ;
Oriol-Rocafiguera, Albert ;
Garcia-Larana, Jose ;
Mateos, Maria-Victoria ;
Sureda, Anna ;
Martinez-Chamorro, Carmen ;
Teresa Cibeira, Maria ;
Aguado, Beatriz ;
Knight, Robert ;
Rosettani, Barbara .
LEUKEMIA & LYMPHOMA, 2012, 53 (09) :1714-1721
[3]  
Altekruse S.F., 2009, SEER Cancer Statistics Review, 1975-2007
[4]  
[Anonymous], 2011, ASH ANN M
[5]   Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma [J].
Benboubker, Lotfi ;
Dimopoulos, Meletios A. ;
Dispenzieri, Angela ;
Catalano, John ;
Belch, Andrew R. ;
Cavo, Michele ;
Pinto, Antonello ;
Weisel, Katja ;
Ludwig, Heinz ;
Bahlis, Nizar ;
Banos, Anne ;
Tiab, Mourad ;
Delforge, Michel ;
Cavenagh, Jamie ;
Geraldes, Catarina ;
Lee, Je-Jung ;
Chen, Christine ;
Oriol, Albert ;
de la Rubia, Javier ;
Qiu, Lugui ;
White, Darrell J. ;
Binder, Daniel ;
Anderson, Kenneth ;
Fermand, Jean-Paul ;
Moreau, Philippe ;
Attal, Michel ;
Knight, Robert ;
Chen, Guang ;
Van Oostendorp, Jason ;
Jacques, Christian ;
Ervin-Haynes, Annette ;
Avet-Loiseau, Herve ;
Hulin, Cyrille ;
Facon, Thierry .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) :906-917
[6]   Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials [J].
Bringhen, Sara ;
Victoria Mateos, Maria ;
Zweegman, Sonja ;
Larocca, Alessandra ;
Falcone, Antonietta Pia ;
Oriol, Albert ;
Rossi, Davide ;
Cavalli, Maide ;
Wijermans, Pierre ;
Ria, Roberto ;
Offidani, Massimo ;
Jose Lahuerta, Juan ;
Liberati, Anna Marina ;
Mina, Roberto ;
Callea, Vincenzo ;
Schaafsma, Martijn ;
Cerrato, Chiara ;
Marasca, Roberto ;
Franceschini, Luca ;
Evangelista, Andrea ;
Teruel, Ana-Isabel ;
van der Holt, Bronno ;
Montefusco, Vittorio ;
Ciccone, Giovannino ;
Boccadoro, Mario ;
San Miguel, Jesus ;
Sonneveld, Pieter ;
Palumbo, Antonio .
HAEMATOLOGICA, 2013, 98 (06) :980-987
[7]   Are ongoing trials on hematologic malignancies still excluding older subjects? [J].
Cherubini, Antonio ;
Pierri, Francesca ;
Gasperini, Beatrice ;
Zengarini, Elisa ;
Cerenzia, Annarita ;
Bonifacio, Elisabetta ;
Falcinelli, Flavio ;
Lattanzio, Fabrizia .
HAEMATOLOGICA, 2013, 98 (07) :997-+
[8]   IMWG consensus on risk stratification in multiple myeloma [J].
Chng, W. J. ;
Dispenzieri, A. ;
Chim, C-S ;
Fonseca, R. ;
Goldschmidt, H. ;
Lentzsch, S. ;
Munshi, N. ;
Palumbo, A. ;
Miguel, J. S. ;
Sonneveld, P. ;
Cavo, M. ;
Usmani, S. ;
Durie, B. G. M. ;
Avet-Loiseau, H. .
LEUKEMIA, 2014, 28 (02) :269-277
[9]   An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma [J].
Cocks, K. ;
Cohen, D. ;
Wisloff, F. ;
Sezerc, O. ;
Lee, S. ;
Hippe, E. ;
Gimsing, P. ;
Turesson, I. ;
Hajek, R. ;
Smith, A. ;
Graham, L. ;
Phillips, A. ;
Stead, M. ;
Velikova, G. ;
Brown, J. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (11) :1670-1678
[10]   Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial. [J].
Delforge, Michel ;
Minuk, Leonard ;
Eisenmann, Jean-Claude ;
Arnulf, Bertrand ;
Canepa, Letizia ;
Fragasso, Alberto ;
Leyvraz, Serge ;
Langer, Christian ;
Ezaydi, Yousef ;
Vogl, Dan T. ;
Giraldo-Castellano, Pilar ;
Yoon, Sung-Soo ;
Martins, Angelo ;
Zarnitsky, Charles ;
Barbe, Martine Escoffre ;
Lemieux, Bernard ;
Proskorovsky, Irina ;
Ervin-Haynes, Annette L. ;
Houck, Vanessa ;
Facon, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)